YUAN IA™ | Starting with fertility in Thailand
Not another clinic. The operating layer between Chinese demand and licensed Southeast Asian supply.
Own first-party demand, eligibility, licensed-provider matching, YUAN IA Journey™ and verified service events. Fertility is the first wedge — not the final category.
Shenzhen
Greater Bay Area · Demand
YUAN IA™
YUAN IA Journey™
Thailand Node
Licensed supply · verified service
Southeast Asia
Country nodes after proof
¥294B
Thailand investment applications · 1H 2026
¥224B
Digital-sector applications · 1H 2026
123
ART-certified facilities · Thailand HSS, Mar 2026
Medical · Digital · Services
Strategic Context
Shenzhen · Greater Bay Area · Demand
| Policy direction | YUAN IA capability |
|---|---|
| AI+ / digital-intelligent enablement | RAG, multilingual workflow, task orchestration, human handoff |
| Data governance / international cooperation | Consent, minimisation, transfer register, incident response |
| Healthy China / full-cycle services | Navigation, education, follow-up, quality/SLA |
| Modern services / service consumption | Cross-border healthcare services and verified service revenue |
Thailand is the first operating node, not the end-state. EEC is the proposed Digital HQ / R&D / strategic hub — not the whole company. The intersection of Medical & Health, Digital and High-Value Medical Tourism is sector relevance, not project endorsement.
Proposed YUAN IA fit: Precision Medicine × Regional HQ × Digital / Data Centre
Source: Eastern Economic Corridor Office (EECO) — EEC Capital City (EECiti) · Open the official EECO page →
Public planning graphic for location and zoning context. YUAN IA is a proposed strategic use case — not an official EECO project or government endorsement.
Share of China projects (approx.)
EEC investment-promotion certificates for 2018–2024 show China among the largest foreign sources. In the China project mix, digital is about 13% and medical & health about 1% — an industrial gap for a Medical × Digital × Services use case, not an approved project.
Capital Momentum
123
ART-certified facilities
Thailand HSS, Mar 2026
Expansion Discipline
Stage 1
Legal/data map · 3–5 clinic LOIs · first verified paid cases · base case
Stage 2
Repeatable CAC · positive contribution · quality/SLA · limited adjacency
Stage 3
Workflow reuse >70% · licensing/data path · enterprise demand · upside until approved
Stage 4
Country-node playbook · local entities/partners · security/governance · Series A / later
The base case covers only the Thailand fertility wedge. A second vertical or second country is upside, not a hidden assumption. A country enters the operating plan only with a named owner, legal path, provider pipeline, unit-economics test and stop condition.
Consented Chinese relationships and intent history live in the YUAN IA account layer — not in a salesperson’s pocket.
Structured capabilities, capacity, SLA, languages, pricing boundaries and quality evidence, reusable across clinics.
Which user, data and service can move where — with consent and a legal basis.
Handoffs, completion and service reliability across providers and borders — not chat logs.
Which content, channel, provider and pathway produces verified service and contribution.
Reusable entity, onboarding, data, payment, partner and governance patterns. AI models can be copied; this graph is harder.
Live
V4.0 regional infrastructure thesis completed (17 Aug 2026)
Signed
Clinic LOIs and channel contracts: pending — no unauthorised names
In Due Diligence
Legal map, data map and EECO/BOI pre-consultation path in preparation
Target
100 days: 3–5 clinic LOIs, 50–100 qualified consults, 10–20 confirmed appointments, ≥5 verified paid/treatment starts
Policy relevance ≠ government endorsement. EEC/BOI incentives require formal approval. Sector figures are public-source and subject to diligence.
Capital Plan
¥30M
Strategic Seed / Pre-A in RMB. Discussion materials only; subject to due diligence.
Tranche release
¥12M
Legal/data foundation, MVP, 3–5 clinic LOIs, first real cohort. Product, core team, compliance and small demand tests.
¥9M
Provider integrations, demand scale, AI/R&D. Gate: ≥250 cumulative verified starts by month 12, with repeatable SLA/CAC and contribution improvement.
¥9M
Quality, enterprise proof, EEC/R&D and regional readiness. Gate: months 18–24 network density and governance maturity. A second country is not a calendar milestone.
¥30M
Use of proceeds
| Use | Share | Amount |
|---|---|---|
| China demand & brand | 30% | ¥9M |
| Product / AI / data | 25% | ¥7.5M |
| Journey operations | 15% | ¥4.5M |
| Compliance / legal | 10% | ¥3M |
| EEC setup / R&D | 10% | ¥3M |
| Integrations & quality | 5% | ¥1.5M |
| Reserve | 5% | ¥1.5M |
| Revenue line | Unit economics | Note |
|---|---|---|
| Provider SaaS | ~¥0.15M / clinic / year | Independent of clinical outcomes; must be proven by signed contracts and collections |
| Journey coordination | ~¥13k / verified start | Who pays, when it is earned, and refunds on cancellation are core diligence items |
| Concierge / Enterprise | Journey and white-label portals | Minimum necessary data sharing; enterprise demand is infrastructure proof |
| Year | Paid clinics | Verified starts | Revenue | EBITDA |
|---|---|---|---|---|
| Y1 | 10 | 250 | ¥5.5M | ¥-12.9M |
| Y2 | 25 | 800 | ¥16.3M | ¥-9.7M |
| Y3 | 45 | 1,800 | ¥34.7M | ¥-1.0M |
| Y4 | 65 | 3,200 | ¥59.1M | ¥12.3M |
| Y5 | 85 | 5,000 | ¥89.4M | ¥28.4M |
In this simplified wedge model, cumulative EBITDA bottoms near ¥23.6M, below the ¥30M first round; annual EBITDA turns positive in Y4 and cumulative EBITDA in Y5. Actual cash needs can differ due to tax, working capital, refunds, FX and timing. Not a forecast or return guarantee.
Founder
Founder and Chief Executive Officer
Working languages: Mandarin Chinese, Thai and English
9+
years, China market & digital ops
2.5M+
content views (Dot Property)
7,000+
qualified leads (Dot Property)
20,000+
e-commerce orders (Medicare)
CN / TH / EN
operating languages
Next Step
For qualified investors, government counterparts and strategic partners.
Request data-room accessDirect line
Reach Pang Yuanyuan through these three channels only. There is no public intake form.
This website is provided by YUAN IA Global Health Co., Ltd. (incorporated in Shenzhen, China) for discussion with qualified investors, government bodies and strategic partners. It is not a securities offer, prospectus, investment advice, legal or tax opinion, or medical advice.
Nothing here states or implies approval, guarantee or endorsement by the Chinese government, EECO, BOI or any hospital. EEC/BOI incentives are subject to formal approval.
Product Demo
Start with the member app used from Shenzhen, then the clinic workspace. Two sides of the same digital operating layer. Illustrative data only — no live member files or clinical records.
YUAN IA Journey™ · Member App
Li Wei in Shenzhen sees stage, next step, and her Care Navigator.
Illustrative data. Not a live production system. No health information is collected. Interface language follows the prototype.
